-0.64%, which specializes in genetic testing and DNA sequencing, said Tuesday afternoon that its first-quarter revenue will beat its own projections and estimates that have declined in the wake of the COVID-19 pandemic.Illumina did retract the rest of its guidance for this year due to uncertainty related to the spread of the coronavirus.